Bertilimumab

From Self-sufficiency
Jump to: navigation, search
Bertilimumab
Monoclonal antibody
Type Whole antibody
Source Template:Infobox drug/mab source
Target CCL11 (eotaxin-1)
Identifiers
CAS Number 375348-49-5
ATC code none
Script error: No such module "TemplatePar".Expression error: Unexpected < operator.

Bertilimumab is a human monoclonal antibody that binds to eotaxin-1.

It was discovered by Cambridge Antibody Technology using their phage display technology[1]. Named CAT-213 during early discovery and development by CAT, it was to be used to treat severe allergic disorders[2].

In January 2007, CAT licensed the drug for treatment of allergy disorders to iCo Therapeutics Inc.[3]. iCo Therapeutics Inc. is a Vancouver-based reprofiling company focused on redosing or reformulating drugs with clinical history for new or expanded indications - a so-called 'search and development company'[4].

iCo Therapeutics Inc. renamed the drug from CAT-213 to iCo-008 and, at that stage, planned to initiate a Phase II clinical trial in patients with vernal keratoconjunctivitis[5].

In March 2008, iCo announced iCo-008 had been in 126 patients in Phase I and II clinical trials. The drug substance had been manufactured by Lonza, in its cGMP facilities in Slough, UK. Subsequently iCo moved the drug substance to a fill-finish site for the final stage of manufacturing. iCo reported that the iCo-008 drug product was within specifications and contained a high antibody yield.[6]

References

Cite error: Invalid <references> tag; parameter "group" is allowed only.

Use <references />, or <references group="..." />


  1. http://jpet.aspetjournals.org/cgi/content/abstract/319/3/1395
  2. http://www.ncbi.nlm.nih.gov/pubmed/15573873
  3. http://www.icotherapeutics.com/site/investor-relations/cambridge_antibody_tech_licenses_monoclonal_antibody_treatment_allergy/
  4. http://www.icotherapeutics.com/site/corporate_overview/overview/
  5. http://www.icotherapeutics.com/site/pipeline/ico008/
  6. http://www.icotherapeutics.com/site/investor-relations/ico_therapeutics_provides_ico_008_phase_ii_clinical_update/